

permit the graft to be deployed in a minimally invasive fashion, and b) a combination of coating density, coating tenacity and bioactivity sufficient to permit the coating to substantially prevent endoleaking when deployed and used *in vivo*.

a2
cancel

10. (once amended) An endovascular graft comprising an expandable stent portion and a porous stent cover portion selected from PET and ePTFE, the cover portion being coated with a bioactive agent comprising collagen, wherein the collagen is covalently attached in a thin, conformal coating to the cover portion in a manner sufficient to promote initial thrombus formation followed by long term fibrous tissue ingrowth, and wherein the coating is covalently attached by the activation of photoreactive groups provided by the cover portion, by the bioactive agent, and/or by a linking agent.

a3

14. (once amended) A method according to claim 12 wherein the bioactive agent is covalently attached in the form of a thin, conformal coating on at least an outer surface of the stent cover portion.

Sub B9
a4

19. (once amended) A method according to claim 12 wherein the agent is attached to the cover portion in a manner that provides a) a minimal increase in overall bulk, sufficient to permit the graft to be deployed in a minimally invasive fashion, and b) a combination of coating density, coating tenacity and bioactivity sufficient to permit the coating to substantially prevent endoleaking when deployed and used *in vivo*.

Remarks

Claims 1-21 were pending, with claims 1-7, 9-17 and 19-21 being considered and claims 8 and 18 withdrawn from consideration. Claims 4, 9, 10, 14 and 19 have been amended and claims 8 and 18 have been cancelled above. Upon entry of the present Amendment, claims 1-7, 9-17, and 19-21 will be pending and in condition for allowance.

The Examiner's remarks regarding the Election/Restriction requirement are acknowledged, though Applicants maintain the positions set forth previously.